Imperial College London
Portrait Picture

Prof. Christina Fotopoulou

Faculty of Medicine, Department of Surgery & Cancer

Chair in Gynaecological Cancer Surgery
 
 
 
//

Contact

 

c.fotopoulou

 
 
//

Location

 

Institute of Reproductive and Developmental BiologyHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Matsuo:2015:10.1016/j.ejca.2015.07.012,
author = {Matsuo, K and Hasegawa, K and Yoshino, K and Murakami, R and Hisamatsu, T and Stone, RL and Previs, RA and Hansen, JM and Ikeda, Y and Miyara, A and Hiramatsu, K and Enomoto, T and Fujiwara, K and Matsumura, N and Konishi, I and Roman, LD and Gabra, H and Fotopoulou, C and Sood, AK},
doi = {10.1016/j.ejca.2015.07.012},
journal = {European Journal of Cancer},
pages = {1978--1988},
title = {Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma},
url = {http://dx.doi.org/10.1016/j.ejca.2015.07.012},
volume = {51},
year = {2015}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background:We compared survival outcomes and risk of venous thromboembolism (VTE) among patients with advanced and early-stage ovarian clear cell carcinoma (OCCC) and serous ovarian carcinoma (SOC), as well as potential links with interleukin-6 (IL-6) levels.Methods:A multicenter case-control study was conducted in 370 patients with OCCC and 938 with SOC. In a subset of 200 cases, pretreatment plasma IL-6 levels were examined.Findings:Patients with advanced OCCC had the highest 2-year cumulative VTE rates (advanced OCCC 43.1%, advanced SOC 16.2%, early-stage OCCC 11.9% and early-stage SOC 6.4%, P < 0.0001) and the highest median levels of IL-6 (advanced OCCC 17.8 pg/mL, advanced SOC 9.0 pg/mL, early-stage OCCC 4.2 pg/mL and early-stage SOC 5.0 pg/mL, P = 0.006). Advanced OCCC (hazard ratio [HR] 3.38, P < 0.0001), thrombocytosis (HR 1.42, P = 0.032) and elevated IL-6 (HR 8.90, P = 0.046) were independent predictors of VTE. In multivariate analysis, patients with advanced OCCC had significantly poorer 5-year progression-free and overall survival rates than those with advanced SOC (P < 0.01), and thrombocytosis was an independent predictor of decreased survival outcomes (P < 0.01). Elevated IL-6 levels led to poorer 2-year progression-free survival rates in patients with OCCC (50% versus 87.5%, HR 4.89, P = 0.016) than in those with SOC (24.9% versus 40.8%, HR 1.40, P = 0.07).Interpretation:Advanced OCCC is associated with an increased incidence of VTE and decreased survival outcomes, which has major implications for clinical management of OCCC.
AU  - Matsuo,K
AU  - Hasegawa,K
AU  - Yoshino,K
AU  - Murakami,R
AU  - Hisamatsu,T
AU  - Stone,RL
AU  - Previs,RA
AU  - Hansen,JM
AU  - Ikeda,Y
AU  - Miyara,A
AU  - Hiramatsu,K
AU  - Enomoto,T
AU  - Fujiwara,K
AU  - Matsumura,N
AU  - Konishi,I
AU  - Roman,LD
AU  - Gabra,H
AU  - Fotopoulou,C
AU  - Sood,AK
DO  - 10.1016/j.ejca.2015.07.012
EP  - 1988
PY  - 2015///
SN  - 1879-0852
SP  - 1978
TI  - Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma
T2  - European Journal of Cancer
UR  - http://dx.doi.org/10.1016/j.ejca.2015.07.012
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000360081300016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/43689
VL  - 51
ER  -
Download